The investigation of pharmacokinetic and phar-macodynamic relationships after converting
enzyme inhibitors has been limited up until now. The drug most widely available, captopril …

Abstract Captopril (SQ 14 225) was administered to normotensive, sodium-replete
volunteers in order to investigate the relationships between its haemodynamic effects and …

Abstract Captopril (1 and 4 mg/kg) was administered intravenously to rabbits and plasma
converting enzyme measured using a radioenzymatic technique. Captopril inhibited plasma …

Captopril (Capoten) hasbeen evaluated in the treatment both of hypertension and cardiac
failure (Atkinson & Robertson, 1979). However, it is currently indicated only for severe or …

The di-acid metabolite of enalapril, enalaprilat, and its lysine analogue lisinopril are potent
inhibitors of angiotensin converting enzyme (ACE); they do not contain sulphydryl groups …

The disposition of Captopril, an angiotensin‐converting enzyme inhibitor with
antihypertensive properties, was studied in 10 normal male subjects after a single 100‐mg …

Pharmacodynamics of converting enzyme inhibition - PMC Back to Top Skip to main content
NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content Main …

The late 1950s and early 1960s witnessed a dramatic change in the practice of medicine. At
this time many drugs were introduced into the clinic which for the first time allowed the …

1 Two single doses of 10 mg each of the converting enzyme inhibitor enalapril maleate or
MK‐421 and of its lysine analogue (MK‐521) were administered po to twelve male …

1 The ability of captopril, 150 mg three times daily by mouth, to effect sustained reduction in
plasma angiotensin II, with converse increases in circulating angiotensin I, and in active …